[Polymyositis/dermatomyositis--clinical picture and treatment].
Identifieur interne : 001293 ( Main/Curation ); précédent : 001292; suivant : 001294[Polymyositis/dermatomyositis--clinical picture and treatment].
Auteurs : Branimir Ani ; Mislav CerovecSource :
- Reumatizam [ 0374-1338 ] ; 2012.
Descripteurs français
- KwdFr :
- MESH :
- diagnostic : Dermatomyosite, Polymyosite.
- Dermatomyosite, Humains, Polymyosite.
English descriptors
- KwdEn :
- MESH :
- diagnosis : Dermatomyositis, Polymyositis.
- therapy : Dermatomyositis, Polymyositis.
- Humans.
Abstract
The clinical presentation ofmyositis ranges from a painless muscle weakness to significant myalgia with muscle weakness and constitutional symptoms. Along with muscle and skin affection and constitutional symptoms, the disease can affect lungs, joints, heart and gastrointestinal system. It is important to note that the clinical presentation ofmyositis syndrome may overlap with symptoms of other connective tissue disease in overlap syndromes (SLE, SSCL, RA, SSjö). Common manifestations of the disease are weakness and muscle fatigue, which is the result of skeletal muscles inflammation (usually the proximal group of muscles, bilaterally and symmetrical). Severe forms of the disease with affection of the throat and respiratory muscles can vitally endan- ger patients. Among constitutional (general) symptoms, fever, malaise and weight loss are usually expressed. Skin affection in dermatomyositis can be localized or generalized like vesiculobullous erythroderma. Pathognomonic cutaneous manifestations of dermatomyositis are Gottron's papules and heliotrope erythema. Lungs are most commonly affected organs (with exception of muscles and skin) in polymyositis and dermatomyositis. The affection of lung can sometimes result in fatal outcome (interstitial lung disease, secondary pulmonary hypertension). Cardiac affection is usually subclinical, but can also be expressed as heart failure, acute coronary syndrome or conduction disturbances. Infrequent manifestations of the disease are gastroesophageal reflux, malabsorption, gastrointestinal mucosal ulceration, soft tissue calcification, Raynaud's syndrome, arthralgia/arthritis and some other less common clinical manifestations of the disease. Treatment of polymyositis/dermatomyositis includes immunosuppressive/immunomodulatory therapy and supportive, symptomatic treatment. The basis for myositis treatment are glucocorticoids, which are applied orally in a daily dosage regimen of 0.75 to 1 mg/kg/day, and in severe forms of the disease in the i.v. pulse doses of 1 g/day. Immunosuppressants/immunomodulators are added in the therapy along with glucocorticoids for better control of the disease and to reduce the required dose of glucocorticoids (side effects of longterm high doses glucocorticoide use). The most commonly used immunosuppressive drug is methotrexate at a dose of up to 25 mg/week. Hydroxychloroquine has a good effect on the cutaneous manifestations of the disease. Among other immunosuppressants which are used in the treatment of myositis are azathioprine, cyclosporine (in patients with pulmonary affection), mycophenolate mofetil and tacrolimus. Intravenous immunoglobulins applied parenterally in a dose of 2 g/kg divided into multiple doses showed an excellent clinical effect in patients with affection of the esophagus and throat muscles, in patients with pulmonary affection and in patients with resistant disease. The experience with the biologics is limited to a small number of patients. Physiotherapy is a necessary form of treatment for the recovery of muscle strength in the remission phase of the disease. A prompt treatment of infections and heart failure is sometimes life-saving in patients with myositis. Symptomatic treatment of pain with analgesics and NSAIDs reduces pain, speeds up recovery and improves the quality of life in patients with myositis.
PubMed: 23745455
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000366
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000366
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000342
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000202
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000202
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000202
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001294
Links to Exploration step
pubmed:23745455Curation
No country items
Branimir Ani<affiliation><nlm:affiliation>Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb.</nlm:affiliation>
<wicri:noCountry code="subField">10000 Zagreb</wicri:noCountry>
</affiliation>
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Polymyositis/dermatomyositis--clinical picture and treatment].</title>
<author><name sortKey="Ani, Branimir" sort="Ani, Branimir" uniqKey="Ani B" first="Branimir" last="Ani">Branimir Ani</name>
<affiliation><nlm:affiliation>Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb.</nlm:affiliation>
<wicri:noCountry code="subField">10000 Zagreb</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cerovec, Mislav" sort="Cerovec, Mislav" uniqKey="Cerovec M" first="Mislav" last="Cerovec">Mislav Cerovec</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:23745455</idno>
<idno type="pmid">23745455</idno>
<idno type="wicri:Area/PubMed/Corpus">000366</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000366</idno>
<idno type="wicri:Area/PubMed/Curation">000366</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000366</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000342</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000342</idno>
<idno type="wicri:Area/Ncbi/Merge">000202</idno>
<idno type="wicri:Area/Ncbi/Curation">000202</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000202</idno>
<idno type="wicri:doubleKey">0374-1338:2012:Ani B:polymyositis:dermatomyositis:clinical</idno>
<idno type="wicri:Area/Main/Merge">001294</idno>
<idno type="wicri:Area/Main/Curation">001293</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Polymyositis/dermatomyositis--clinical picture and treatment].</title>
<author><name sortKey="Ani, Branimir" sort="Ani, Branimir" uniqKey="Ani B" first="Branimir" last="Ani">Branimir Ani</name>
<affiliation><nlm:affiliation>Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb.</nlm:affiliation>
<wicri:noCountry code="subField">10000 Zagreb</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cerovec, Mislav" sort="Cerovec, Mislav" uniqKey="Cerovec M" first="Mislav" last="Cerovec">Mislav Cerovec</name>
</author>
</analytic>
<series><title level="j">Reumatizam</title>
<idno type="ISSN">0374-1338</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dermatomyositis (diagnosis)</term>
<term>Dermatomyositis (therapy)</term>
<term>Humans</term>
<term>Polymyositis (diagnosis)</term>
<term>Polymyositis (therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Dermatomyosite ()</term>
<term>Dermatomyosite (diagnostic)</term>
<term>Humains</term>
<term>Polymyosite ()</term>
<term>Polymyosite (diagnostic)</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dermatomyositis</term>
<term>Polymyositis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Dermatomyosite</term>
<term>Polymyosite</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dermatomyositis</term>
<term>Polymyositis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Dermatomyosite</term>
<term>Humains</term>
<term>Polymyosite</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The clinical presentation ofmyositis ranges from a painless muscle weakness to significant myalgia with muscle weakness and constitutional symptoms. Along with muscle and skin affection and constitutional symptoms, the disease can affect lungs, joints, heart and gastrointestinal system. It is important to note that the clinical presentation ofmyositis syndrome may overlap with symptoms of other connective tissue disease in overlap syndromes (SLE, SSCL, RA, SSjö). Common manifestations of the disease are weakness and muscle fatigue, which is the result of skeletal muscles inflammation (usually the proximal group of muscles, bilaterally and symmetrical). Severe forms of the disease with affection of the throat and respiratory muscles can vitally endan- ger patients. Among constitutional (general) symptoms, fever, malaise and weight loss are usually expressed. Skin affection in dermatomyositis can be localized or generalized like vesiculobullous erythroderma. Pathognomonic cutaneous manifestations of dermatomyositis are Gottron's papules and heliotrope erythema. Lungs are most commonly affected organs (with exception of muscles and skin) in polymyositis and dermatomyositis. The affection of lung can sometimes result in fatal outcome (interstitial lung disease, secondary pulmonary hypertension). Cardiac affection is usually subclinical, but can also be expressed as heart failure, acute coronary syndrome or conduction disturbances. Infrequent manifestations of the disease are gastroesophageal reflux, malabsorption, gastrointestinal mucosal ulceration, soft tissue calcification, Raynaud's syndrome, arthralgia/arthritis and some other less common clinical manifestations of the disease. Treatment of polymyositis/dermatomyositis includes immunosuppressive/immunomodulatory therapy and supportive, symptomatic treatment. The basis for myositis treatment are glucocorticoids, which are applied orally in a daily dosage regimen of 0.75 to 1 mg/kg/day, and in severe forms of the disease in the i.v. pulse doses of 1 g/day. Immunosuppressants/immunomodulators are added in the therapy along with glucocorticoids for better control of the disease and to reduce the required dose of glucocorticoids (side effects of longterm high doses glucocorticoide use). The most commonly used immunosuppressive drug is methotrexate at a dose of up to 25 mg/week. Hydroxychloroquine has a good effect on the cutaneous manifestations of the disease. Among other immunosuppressants which are used in the treatment of myositis are azathioprine, cyclosporine (in patients with pulmonary affection), mycophenolate mofetil and tacrolimus. Intravenous immunoglobulins applied parenterally in a dose of 2 g/kg divided into multiple doses showed an excellent clinical effect in patients with affection of the esophagus and throat muscles, in patients with pulmonary affection and in patients with resistant disease. The experience with the biologics is limited to a small number of patients. Physiotherapy is a necessary form of treatment for the recovery of muscle strength in the remission phase of the disease. A prompt treatment of infections and heart failure is sometimes life-saving in patients with myositis. Symptomatic treatment of pain with analgesics and NSAIDs reduces pain, speeds up recovery and improves the quality of life in patients with myositis.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001293 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001293 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:23745455 |texte= [Polymyositis/dermatomyositis--clinical picture and treatment]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:23745455" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |